Background <p>T-cell immunoglobulin and mucin-domain containing 3 (TIM-3) is an inhibitory receptor linked to decreased antitumor activity of immune cells. S095018 is a human anti-TIM-3 IgG2 antibody that blocks the binding of phosphatidyl serine to TIM-3. Sym021 is a humanized IgG1 antibody that inhibits the binding of programmed cell death protein-1 (PD-1) to its ligands programmed death-ligand 1 (PD-L1) and…
Phase Ib multicenter study of anti-TIM-3 (S095018/Sym023) in combination with anti-PD-1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancer
Journal for ImmunoTherapy of Cancer | | Ghiringhelli, F., Kim, R., Macarulla, T., Moreno, I., Abdul Razak, A., Rodon Ahnert, J., Liao, C.-Y., Davis, S. L., Mahipal, A., Marron, T., Raimbourg, J., Kaplon, H., Geronimi, J., Harouki, N., Rodrigues, C., Darcel, P., Jakobsen, J. S., Skartved, N., Hald, R., Lopez-Ravnborg, D., He, P., Ianopoulos, X., Askoxylakis, V., Lakhani, N.
Topics: cervical-cancer, immunotherapy, clinical-trials, research
Read the full article at Journal for ImmunoTherapy of Cancer